Aim: Our aim was to investigate the relationships between the degree of IGF2 methylation and the metabolic status in obese children and adolescents. Subjects and Methods: Eighty-five obese subjects aged 11.6 ± 2.1 years were studied. Anthropometry, metabolic parameters, blood pressure and body composition were assessed. DNA methylation analysis was performed by restriction enzyme digestion assay. The study population was subdivided into two groups according to the percentage of IGF2 cytidine-guanosine (CpG) island methylation. Results: Twenty-two subjects showed intermediate methylation (a percentage of CpG site methylation comprised between 10 and 60%), 56 were hypomethylated (percentage of methylation lower than 10%), and only 1 showed a high rate of hypermethylation (percentage of methylation above 60%). Children with intermediate methylation showed significantly higher levels of triglycerides (107.6 ± 41.99 vs. 76.6 ± 30.18 mg/dl, p < 0.005) and a higher triglyceride/high-density lipoprotein-cholesterol ratio (2.23 ± 0.98 vs. 1.79 ± 0.98, p < 0.02) compared with hypomethylated children. Conclusions: These preliminary findings show for the first time a relationship between IGF2 methylation pattern and lipid profile in obese children. Although the correlation does not imply causation, if our findings are confirmed in further studies, IGF2 methylation might represent an epigenetic marker of metabolic risk.

Keywords:
IGF2, Obesity, Dyslipidemia
1.
Gluckman P, Hanson M, Pinal C: The developmental origins of adult disease. Matern Child Nutr 2005;1:130-141.
2.
Barker D, Winter P, Osmond C, Margetts B, Simmonds S: Weight in infancy and death from ischaemic heart disease. Lancet 1989;2:577-580.
3.
Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM: Type 2 (non-insulin-dependent) diabetes-mellitus, hypertension and hyperlipemia (syndrome X) - relation to reduced fetal growth. Diabetologia 1993;36:62-67.
4.
Barker DJ, Martyn CN, Osmond C, Hales CN, Fall CH: Growth in utero and serum cholesterol concentrations in adult life. BMJ 1993;307:1524-1527.
5.
Barker D, Osmond C, Forsén T, Kajantie E, Eriksson J: Trajectories of growth among children who have coronary events as adults. N Engl J Med 2005;353:1802-1809.
6.
Ravelli A, van der Meulen J, Michels R, Osmond C, Barker D, Hales C, Bleker O: Glucose tolerance in adults after prenatal exposure to famine. Lancet 1998;351:173-177.
7.
Eriksson J, Forsén T, Tuomilehto J, Jaddoe V, Osmond C, Barker D: Effects of size at birth and childhood growth on the insulin resistance syndrome in elderly individuals. Diabetologia 2002;45:342-348.
8.
Gluckman P, Hanson M, Buklijas T, Low F, Beedle A: Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol 2009;5:401-408.
9.
Liguori A, Puglianiello A, Germani D, Deodati A, Peschiaroli E, Cianfarani S: Epigenetic changes predisposing to type 2 diabetes in intrauterine growth retardation. Front Endocrinol (Lausanne) 2010;1:5.
10.
Schübeler D, Lorincz M, Cimbora D, Telling A, Feng Y, Bouhassira E, Groudine M: Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation. Mol Cell Biol 2000;20:9103-9112.
11.
Reik W, Constância M, Fowden A, Anderson N, Dean W, Ferguson-Smith A, Tycko B, Sibley C: Regulation of supply and demand for maternal nutrients in mammals by imprinted genes. J Physiol 2003;547:35-44.
12.
Sibley CP, Coan PM, Ferguson-Smith AC, Dean W, Hughes J, Smith P, Reik W, Burton GJ, Fowden AL, Constância M: Placental-specific insulin-like growth factor 2 (IGF2) regulates the diffusional exchange characteristics of the mouse placenta. Proc Natl Acad Sci USA 2004;101:8204-8208.
13.
Liang L, Guo WH, Esquiliano DR, Asai M, Rodriguez S, Giraud J, Kushner JA, White MF, Lopez MF: Insulin-like growth factor 2 and the insulin receptor, but not insulin, regulate fetal hepatic glycogen synthesis. Endocrinology 2010;151:741-747.
14.
Rossetti L, Barzilai N, Chen W, Harris T, Yang D, Rogler CE: Hepatic overexpression of insulin-like growth factor-II in adulthood increases basal and insulin-stimulated glucose disposal in conscious mice. J Biol Chem 1996;271:203-208.
15.
O'Dell SD, Miller GJ, Cooper JA, Hindmarsh PC, Pringle PJ, Ford H, Humphries SE, Day IN: Apal polymorphism in insulin-like growth factor II (IGF2) gene and weight in middle-aged males. Int J Obes Relat Metab Disord 1997;21:822-825.
16.
Gaunt TR, Cooper JA, Miller GJ, Day IN, O'Dell SD: Positive associations between single nucleotide polymorphisms in the IGF2 gene region and body mass index in adult males. Hum Mol Genet 2001;10:1491-1501.
17.
Gu D, O'Dell SD, Chen XH, Miller GJ, Day IN: Evidence of multiple causal sites affecting weight in the IGF2-INS-TH region of human chromosome 11. Hum Genet 2002;110:173-181.
18.
Zhang W, Maniatis N, Rodriguez S, Miller GJ, Day IN, Gaunt TR, Collins A, Morton NE: Refined association mapping for a quantitative trait: weight in the H19-IGF2-INS-TH region. Ann Hum Genet 2006;70:848-856.
19.
Le Stunff C, Fallin D, Bougnères P: Paternal transmission of the very common class I INS VNTR alleles predisposes to childhood obesity. Nat Genet 2001;29:96-99.
20.
Rice T, Chagnon YC, Pérusse L, Borecki IB, Ukkola O, Rankinen T, Gagnon J, Leon AS, Skinner JS, Wilmore JH, Bouchard C, Rao DC: A genomewide linkage scan for abdominal subcutaneous and visceral fat in black and white families: The HERITAGE Family Study. Diabetes 2002;51:848-855.
21.
Faienza MF, Santoro N, Lauciello R, Calabrò R, Giordani L, Di Salvo G, Ventura A, Delvecchio M, Perrone L, Del Giudice EM, Cavallo L: IGF2 gene variants and risk of hypertension in obese children and adolescents. Pediatr Res 2010;67:340-344.
22.
Rodríguez S, Gaunt TR, O'Dell SD, Chen XH, Gu D, Hawe E, Miller GJ, Humphries SE, Day IN: Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits. Hum Mol Genet 2004;13:715-725.
23.
Kadlecová M, Dobesová Z, Zicha J, Kunes J: Abnormal IGF2 gene in Prague hereditary hypertriglyceridemic rats: its relation to blood pressure and plasma lipids. Mol Cell Biochem 2008;314:37-43.
24.
Perkins E, Murphy SK, Murtha AP, Schildkraut J, Jirtle RL, Demark-Wahnefried W, Forman MR, Kurtzberg J, Overcash F, Huang Z, Hoyo C: Insulin-like growth factor 2/H19 methylation at birth and risk of overweight and obesity in children. J Pediatr 2012;161:31-39.
25.
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240-1243.
26.
Bertino E, Spada E, Occhi L, Coscia A, Giuliani F, Gagliardi L, Gilli G, Bona G, Fabris C, De Curtis M, Milani S: Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr 2010;51:353-361.
27.
Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F, Gargantini L, Greggio N, Tonini G, Cicognani A: Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006;29:581-593.
28.
Tanner JM: Growth and maturation during adolescence. Nutr Rev 1981;39:43-55.
29.
Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP: Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-1672.
30.
Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
31.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
32.
Brufani C, Tozzi A, Fintini D, Ciampalini P, Grossi A, Fiori R, Kiepe D, Manco M, Schiaffini R, Porzio O, Cappa M, Barbetti F: Sexual dimorphism of body composition and insulin sensitivity across pubertal development in obese caucasian subjects. Eur J Endocrinol 2009;160:769-775.
33.
Holemon H, Korshunova Y, Ordway JM, Bedell JA, Citek RW, Lakey N, Leon J, Finney M, McPherson JD, Jeddeloh JA: Methylscreen: DNA methylation density monitoring using quantitative PCR. Biotechniques 2007;43:683-693.
34.
Cianfarani S: Insulin-like growth factor-II: new roles for an old actor. Front Endocrinol (Lausanne) 2012;3:118.
35.
Painter R, Roseboom T, Bleker O: Prenatal exposure to the Dutch famine and disease in later life: an overview. Reprod Toxicol 2005;20:345-352.
36.
Painter RC, de Rooij SR, Bossuyt PM, Simmers TA, Osmond C, Barker DJ, Bleker OP, Roseboom TJ: Early onset of coronary artery disease after prenatal exposure to the Dutch famine. Am J Clin Nutr 2006;84:322-327, quiz 466-467.
37.
Roseboom T, de Rooij S, Painter R: The Dutch famine and its long-term consequences for adult health. Early Hum Dev 2006;82:485-491.
38.
Heijmans B, Tobi E, Stein A, Putter H, Blauw G, Susser E, Slagboom P, Lumey L: Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA 2008;105:17046-17049.
39.
Tobi EW, Slagboom PE, van Dongen J, Kremer D, Stein AD, Putter H, Heijmans BT, Lumey LH: Prenatal famine and genetic variation are independently and additively associated with DNA methylation at regulatory loci within IGF2/H19. PLoS One 2012;7:e37933.
40.
Hoyo C, Murtha AP, Schildkraut JM, Jirtle RL, Demark-Wahnefried W, Forman MR, Iversen ES, Kurtzberg J, Overcash F, Huang Z, Murphy SK: Methylation variation at IGF2 differentially methylated regions and maternal folic acid use before and during pregnancy. Epigenetics 2011;6:928-936.
41.
Gong L, Pan YX, Chen H: Gestational low protein diet in the rat mediates IGF2 gene expression in male offspring via altered hepatic DNA methylation. Epigenetics 2010;5:619-626.
42.
Murphy R, Ibáñez L, Hattersley A, Tost J: IGF2/H19 hypomethylation in a patient with very low birthweight, preocious pubarche and insulin resistance. BMC Med Genet 2012;13:42.
43.
Gardan D, Gondret F, Van den Maagdenberg K, Buys N, De Smet S, Louveau I: Lipid metabolism and cellular features of skeletal muscle and subcutaneous adipose tissue in pigs differing in IGF-II genotype. Domest Anim Endocrinol 2008;34:45-53.
44.
Aslan O, Hamill RM, Davey G, McBryan J, Mullen AM, Gispert M, Sweeney T: Variation in the IGF2 gene promoter region is associated with intramuscular fat content in porcine skeletal muscle. Mol Biol Rep 2012;39:4101-4110.
45.
Sinha MK, Buchanan C, Raineri-Maldonado C, Khazanie P, Atkinson S, DiMarchi R, Caro JF: IGF-II receptors and IGF-II-stimulated glucose transport in human fat cells. Am J Physiol 1990;258:E534-E542.
46.
Siddals KW, Westwood M, Gibson JM, White A: IGF-binding protein-1 inhibits IGF effects on adipocyte function: implications for insulin-like actions at the adipocyte. J Endocrinol 2002;174:289-297.
47.
Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA: Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 1990;9:2409-2413.
48.
Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R: Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623.
49.
Pandini G, Conte E, Medico E, Sciacca L, Vigneri R, Belfiore A: IGF-II binding to insulin receptor isoform a induces a partially different gene expression profile from insulin binding. Ann NY Acad Sci 2004;1028:450-456.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.